ANXA1 and infection: Our findings that AnxA1 did not initially prime or enhance an antiviral response in the target tissue, together with our observation that AnxA1-treated primary lung tissue cells are equally susceptible to PR8 infection compared with control cells, pointed to an immune cell-mediated enhanced viral clearance at early steps in infection, thus limiting viral spread and immune-induced lung injury.